

02 Dec 2021 | News

Novartis Will Co-Develop UCB's Alpha-Syn Inhibitor For Parkinson's

by [Joseph Haas](#)

Deal Snapshot: Seeking to bring a disease-modifying Parkinson's drug to market, Novartis will team with UCB on developing and commercializing UCB0599, a Phase II oral alpha-synuclein inhibitor.

Who: Novartis/UCB

What: Novartis will co-develop and co-commercialize a potentially disease-modifying, small molecule Parkinson's disease drug that UCB has in Phase II.

Why: Novartis is wagering that inhibiting alpha-synuclein pathology could provide a way to halt progression of Parkinson's, differing from currently approved therapies that only address disease symptoms.

Financials: Novartis is paying UCB \$150m up front, with potential for earnouts up to \$1.5bn.

Analysis: In tandem with its R&D day presentation on 2 December, [Novartis AG](#) announced that it is licensing co-development and co-commercialization rights to UCB0599, a Phase II oral, potentially disease-modifying alpha-synuclein inhibitor for Parkinson's disease from [UCB S.A.](#) The big pharma will pay UCB \$150m up front under the deal, which also confers option rights to a second Parkinson's candidate, the Phase I alpha-syn-targeting monoclonal antibody UCB7853.

During the R&D call, Novartis's global head-neuroscience development unit Norman Putski called UCB0599 "the leading oral molecule targeting alpha-synuclein misfolding." Alpha-syn pathology is an increasingly competitive development space in neurodegenerative

Novartis Poised To Grow Despite \$9bn In LOEs Coming, CEO Says

By [Jessica Merrill](#)

disease, being investigated by companies including [Roche Holding AG](#), [Prothena Corporation plc](#), [AbbVie Inc.](#) and [BioArctic AB](#) for both Parkinson's and Alzheimer's disease. (Also see "[Parkinson's Disease: Novel Science And Collaborations Fuel Progress](#)" - In Vivo, 22 Nov, 2019.)

Putski called the deal "a great strategic fit" for Novartis's ambition to develop and market disease-modifying therapies for severe neurodegenerative disease. "Alpha-synuclein is a super exciting target for Parkinson's disease modification," he said. "It is neuropathologically and genetically validated and in animal models [of UCB0599], we have seen really strong data. We have seen reduced alpha-synuclein, we have seen an increase of dopamine transporters and we've also seen an improved motor function in these models."

Under the deal, UCB can earn up to \$1.5bn in development, regulatory and sales-based milestone fees. The companies will co-fund development of UCB0599 going forward, and Novartis can opt in to co-develop UCB7853 if it likes what it sees when Phase I data report out. The partners will split commercialization responsibilities, with Belgium-based UCB handling Europe and Japan, while Novartis will take the US and rest-of-world responsibilities. The deal announcement does not reference any cross-royalty rights for either company.

Novartis's pipeline currently lists no clinical candidates for Parkinson's disease. In 2013, the firm ended development of mavoglurant (AFQ056), an oral metabotropic glutamate 5 (mGluR5) antagonist for Parkinson's dyskinesia, after the candidate failed to show efficacy in Phase II trials. (Also see "[Novartis drops PhII Parkinson's program](#)" - Scrip, 23 Oct, 2013.)

02 Dec 2021

CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.

[Read the full article here](#)